<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="pmcid: 7066101781 doi: 10.1007/s00281-020-00781-5 : Review Role of viruses in" exact="asthma" post="JarttiTuomas1BønnelykkeKlaus2EleniusVarpu1http://orcid.org/0000-0001-6613-2012FeleszkoWojciechwojciech.feleszko@wum.edu.pl3[1], grid.410552.70000 0004 0628 215XDepartment of Paediatrics, Turku University"/>
 <result pre="Abstract Respiratory viral infections are the most important triggers of" exact="asthma" post="exacerbations. Rhinovirus (RV), the common cold virus, is clearly"/>
 <result pre="the most important triggers of asthma exacerbations. Rhinovirus (RV), the" exact="common cold" post="virus, is clearly the most prevalent pathogen constantly circulating"/>
 <result pre="and association with specific risk genes in people predisposed to" exact="asthma" post="development (CDHR3). Decreased interferon responses, disrupted airway epithelial barrier,"/>
 <result pre="higher for those who suffer from severe RV-induced wheezing. The" exact="asthma" post="development associated with these viruses has unique mechanisms, but"/>
 <result pre="that inhibit inflammation (corticosteroids, omalizumab) effectively decrease RV-induced wheezing and" exact="asthma" post="exacerbations. The anti-RSV monoclonal antibody, palivizumab, decreases the risk"/>
 <result pre="personal and environmental risk factors and inflammatory mechanisms leading to" exact="asthma" post="is crucial in developing new strategies for the prevention"/>
 <result pre="Respira Introduction Approximately 8–9% of children and adults suffer from" exact="asthma" post="in Europe, and it is estimated that an equal"/>
 <result pre="have asthma-like symptoms [1]. Fortunately, in the majority of patients," exact="asthma" post="is mild, but severe asthma occurs in 5–10% of"/>
 <result pre="in the majority of patients, asthma is mild, but severe" exact="asthma" post="occurs in 5–10% of them [2]. The early stages"/>
 <result pre="recurrent wheezing before school age [3]. Thus, wheezing illnesses and" exact="asthma" post="pose a significant health and socioeconomic burden in the"/>
 <result pre="decreasing to 80% in adults [4–6]. Especially, rhinovirus (RV), the" exact="common cold" post="virus, is clearly the most common single trigger of"/>
 <result pre="of wheezing children and up to 83% of adults with" exact="asthma" post="[4, 5]. Moreover, it is currently the most potent"/>
 <result pre="is currently the most potent objective risk factor of school-age" exact="asthma" post="among young wheezing children, odds rations (OR) reaching 45"/>
 <result pre="12 months [3, 8] but also decreasing the incidence of" exact="asthma" post="by 30% in a 4–7 years follow-up [9, 10]."/>
 <result pre="long-term follow-up [11]. Whether respiratory viruses are causative agents of" exact="asthma" post="or just secondary to a certain underlying condition, they"/>
 <result pre="asthma, we are likely to better understand the pathogenesis of" exact="asthma" post="and to identify novel targets for preventive strategies. The"/>
 <result pre="review the role of virus infections in the pathogenesis of" exact="asthma" post="inception and exacerbations, as well as to discuss interrelated"/>
 <result pre="well as to discuss interrelated protective and risk factors of" exact="asthma" post="and treatment options. Virus etiology from bronchiolitis to asthma"/>
 <result pre="risk factors of asthma and treatment options. Virus etiology from" exact="bronchiolitis" post="to asthma Respiratory virus infections play a significant role"/>
 <result pre="of asthma and treatment options. Virus etiology from bronchiolitis to" exact="asthma" post="Respiratory virus infections play a significant role in all"/>
 <result pre="bilateral whistling sound during expiration accompanied by dyspnea) illnesses from" exact="bronchiolitis" post="to asthma. Virus detection rates using PCR have reached"/>
 <result pre="100% in bronchiolitis, 85–95% in children with recurrent wheezing or" exact="asthma" post="exacerbation, and 80% in adults with asthma exacerbation [3]."/>
 <result pre="recurrent wheezing or asthma exacerbation, and 80% in adults with" exact="asthma" post="exacerbation [3]. The virus coinfection rate is typically 10–40%"/>
 <result pre="of virus detection [3]. According to the majority of guidelines," exact="bronchiolitis" post="is generally defined as virus infection of the lower"/>
 <result pre="reach 10–25%) followed by the parainfluenza virus, adenovirus, coronavirus, and" exact="influenza" post="virus each of which typically make less than 10%"/>
 <result pre="than 10% (Fig. 1). In children with recurrent wheezing and" exact="asthma" post="exacerbation, as well as adults with asthma exacerbation, RV"/>
 <result pre="recurrent wheezing and asthma exacerbation, as well as adults with" exact="asthma" post="exacerbation, RV clearly dominates as a trigger [4, 12]."/>
 <result pre="has reached 76–83% in adults. Fig. 1 Virus etiology from" exact="bronchiolitis" post="and childhood wheezing to asthma. RSV, respiratory syncytial virus;"/>
 <result pre="RSV, respiratory syncytial virus; RV, rhinovirus; hBoV, human bocavirus; Flu," exact="influenza" post="virus; EV, enteroviruses; MPV, metapneumovirus; PIV, parainfluenza virus; AdV,"/>
 <result pre="more severe course of illness than RV-B [15]. Nevertheless, the" exact="common cold" post="is the main type of illness. Up to 35%"/>
 <result pre="most common RV species among hospitalized and intensive care unit" exact="asthma" post="patients [18]. Patients with CDHR3 (cadherin-related family member 3)"/>
 <result pre="asthma patients [18]. Patients with CDHR3 (cadherin-related family member 3)" exact="asthma" post="risk allele and atopic individuals have been more susceptible"/>
 <result pre="may slightly increase the risk of exacerbation in children whose" exact="asthma" post="is of greater severity [3, 21]. Respiratory syncytial virus"/>
 <result pre="with its close relative, metapneumovirus, may be severe and cause" exact="bronchiolitis" post="[14]. However, reinfections, which typically occur annually, are mild."/>
 <result pre="acquired protective antibodies [6]. Influenza virus infection may contribute to" exact="asthma" post="attacks in adults, but due to effective vaccination programs,"/>
 <result pre="typically cause just upper airway infections. Genetics and epigenetics of" exact="asthma" post="and virus susceptibility Asthma is a highly heritable disease"/>
 <result pre="studies of more than 50%, and even higher for childhood" exact="asthma" post="[23]. Genetics is, therefore, one important tool for understanding"/>
 <result pre="mechanisms of asthma. Our knowledge of the genetic background of" exact="asthma" post="has increased rapidly during recent years through methodological advances"/>
 <result pre="GWAS have now identified more than 100 genes/loci associated with" exact="asthma" post="and related traits, with the strongest signal seen for"/>
 <result pre="susceptibility genes are related to the immune system. The first" exact="asthma" post="locus discovered in GWAS, approximately 10 years ago, was"/>
 <result pre="chromosome 17q21 locus [25]. It is still the strongest known" exact="asthma" post="locus, and it is particularly associated with childhood-onset asthma"/>
 <result pre="known asthma locus, and it is particularly associated with childhood-onset" exact="asthma" post="and asthma with severe exacerbations [26]. Interestingly, the 17q21"/>
 <result pre="locus, and it is particularly associated with childhood-onset asthma and" exact="asthma" post="with severe exacerbations [26]. Interestingly, the 17q21 asthma locus"/>
 <result pre="asthma and asthma with severe exacerbations [26]. Interestingly, the 17q21" exact="asthma" post="locus is strongly associated with increased risk of early"/>
 <result pre="early viral wheezing have a much higher risk of later" exact="asthma" post="if they carry 17q21 risk variants [27]. Also, 17q21"/>
 <result pre="increased risk of early wheeze, but also more protected against" exact="asthma" post="when exposed to a farming environment or pets in"/>
 <result pre="clues to the mechanisms of viral infections and asthma. Another" exact="asthma" post="risk gene, CDHR3, was discovered in a GWAS of"/>
 <result pre="risk gene, CDHR3, was discovered in a GWAS of childhood" exact="asthma" post="with recurrent acute hospitalizations before 6 years of age"/>
 <result pre="targeting CDHR3 might be a strategy for preventing rhinovirus-C triggered" exact="asthma" post="exacerbations. Genetic discoveries in GWAS require a very large"/>
 <result pre="se have not yet been performed. One smaller GWAS of" exact="bronchiolitis" post="was performed without genome-wide significant findings [34]. Candidate gene"/>
 <result pre="been associated with asthma, indicating that the association between RSV" exact="bronchiolitis" post="and later asthma development might partly be explained by"/>
 <result pre="asthma, indicating that the association between RSV bronchiolitis and later" exact="asthma" post="development might partly be explained by shared genetics. Epigenetics,"/>
 <result pre="the role of methylation in eosinophils in the pathogenesis of" exact="asthma" post="[36]. Since methylation is tissue-specific, it might be crucial"/>
 <result pre="found several differentially methylated sites associated with allergic sensitization and" exact="asthma" post="[37, 38]. In order to understand the genomics of"/>
 <result pre="asthma [37, 38]. In order to understand the genomics of" exact="asthma" post="and virus infections, we need more studies that combine"/>
 <result pre="and improve treatment and prevention of disease. Risk factors of" exact="asthma" post="Severe acute bronchiolitis or early wheezing is associated with"/>
 <result pre="and prevention of disease. Risk factors of asthma Severe acute" exact="bronchiolitis" post="or early wheezing is associated with an increased risk"/>
 <result pre="early wheezing is associated with an increased risk of subsequent" exact="asthma" post="[3]. This disease may persist until early adulthood, and"/>
 <result pre="atopy (Fig. 2) [3]. Coexpression of aeroallergen sensitization or 17q21" exact="asthma" post="risk alleles increased the odds ratios to the level"/>
 <result pre="[7, 19, 27, 40, 41]. Fig. 2 Major factors influencing" exact="asthma" post="risk in young children suffering from bronchiolitis. RV, rhinovirus;"/>
 <result pre="fatty acids Before the discovery of the link between RV-induced" exact="bronchiolitis" post="and later asthma, it was long thought that RSV"/>
 <result pre="(Fig. 2). Several studies have reported an association between RSV" exact="bronchiolitis" post="and school-age asthma but not with atopy, excluding one"/>
 <result pre="studies have reported an association between RSV bronchiolitis and school-age" exact="asthma" post="but not with atopy, excluding one relatively small cohort"/>
 <result pre="Other risk factors include young age, parental smoking, and common" exact="asthma" post="risk genes [3, 14]. Unlike with RV, RSV causes"/>
 <result pre="common perception is that RSV infection is not causal to" exact="asthma" post="or atopy development. Children with RSV infection are likely"/>
 <result pre="recently reviewed the main non-viral risk and protective factors of" exact="asthma" post="and summarized in Fig. 2 [3, 14]. Rapid urbanization,"/>
 <result pre="the loss of biodiversity, promote chronic non-communicable illnesses such as" exact="asthma" post="and allergies [42]. Exposure to pollutants such as NO2"/>
 <result pre="as NO2 and high exposure to allergens in children with" exact="allergic asthma" post="increase the severity of virus-induced exacerbations of asthma. Maternal"/>
 <result pre="NO2 and high exposure to allergens in children with allergic" exact="asthma" post="increase the severity of virus-induced exacerbations of asthma. Maternal"/>
 <result pre="has mainly abolished its effect [44]. Common protective factors of" exact="allergy" post="and asthma include a healthy lifestyle (healthy nutrition, exercise,"/>
 <result pre="abolished its effect [44]. Common protective factors of allergy and" exact="asthma" post="include a healthy lifestyle (healthy nutrition, exercise, outdoor activities),"/>
 <result pre="there is evidence of a viral trigger in most acute" exact="asthma" post="episodes. However, also, bacteria might play an important role"/>
 <result pre="might play an important role in the pathology of acute" exact="asthma" post="symptoms. As an example, young children with acute wheezy"/>
 <result pre="in the airways of asymptomatic infants and later development of" exact="asthma" post="[48]. Also, the gut microbiome, a putative risk factor"/>
 <result pre="to contribute to the severity of respiratory tract illnesses and" exact="asthma" post="exacerbations [50]. At the epidemiological level, the seasonal peaks"/>
 <result pre="a randomized trial resulted in subsequent reduced risk of virus-associated" exact="pneumonia" post="[52]. There is also evidence of interaction between viruses"/>
 <result pre="importance of assessing both bacteria and viruses in studies of" exact="asthma" post="etiology in order to address their individual roles and"/>
 <result pre="individual roles and the impact of their interaction. Pathogenesis of" exact="asthma" post="Asthma is a syndrome characterized by intermittent attacks of"/>
 <result pre="middle-aged obese, and elderly late-onset). An important molecular mechanism of" exact="asthma" post="is the chronic inflammation of conducting airways, even during"/>
 <result pre="even during asymptomatic periods. This inflammation is different in various" exact="asthma" post="endotypes and may broadly be divided into Th2 high"/>
 <result pre="IL-5, and IL-13 that stimulate Th2 type immunity characterized by" exact="eosinophilia" post="and high antibody titers (Fig. 3) [57]. Th2 type"/>
 <result pre="but it is also associated with the atopic disease; allergy," exact="allergic rhinitis," post="and asthma [58]. Th2 type responses are mediated by"/>
 <result pre="also associated with the atopic disease; allergy, allergic rhinitis, and" exact="asthma" post="[58]. Th2 type responses are mediated by eosinophils, basophils,"/>
 <result pre="Increased production of type 2 cytokines leads to allergen-triggered IgE" exact="hypersensitivity" post="and activation of mast cells, basophils, eosinophils, airways epithelial"/>
 <result pre="impacted by environmental exposures and type 2 immune responses in" exact="asthma" post="pathogenesis. Exposure to air pollutants (cigarette smoke, diesel particle,"/>
 <result pre="rhinovirus-A, rhinovirus-B, rhinovirus-C; RSV-A, RSV-B, respiratory syncytial virus-A, virus-B Childhood" exact="asthma" post="is often associated with other allergic diseases, such as"/>
 <result pre="associated with other allergic diseases, such as atopic eczema and" exact="allergic rhinitis." post="Th2 type inflammation in the airways often starts in"/>
 <result pre="initiates a cascade that leads to the development of childhood" exact="asthma" post="(Figs. 3 and 4). The reason why this Th2"/>
 <result pre="viruses) and host (genetic, microbiome) factors shape the risk of" exact="asthma" post="development and predispose to different asthma phenotypes. B) Environmental"/>
 <result pre="shape the risk of asthma development and predispose to different" exact="asthma" post="phenotypes. B) Environmental exposures to allergens (animal, pollen, mold),"/>
 <result pre="viruses, cigarette smoke, and air pollution are known triggers for" exact="asthma" post="exacerbations. Thunderstorms are associated with asthma exacerbations. Thunderstorms produce"/>
 <result pre="are known triggers for asthma exacerbations. Thunderstorms are associated with" exact="asthma" post="exacerbations. Thunderstorms produce ozone and release allergen-bearing small particles"/>
 <result pre="particles that irritate airways. Avoidance of environmental exposures can improve" exact="asthma" post="control and reduce exacerbations Having allergic sensitization and eczema"/>
 <result pre="wheezing with rhinovirus are all risk factors of having atopic" exact="asthma" post="at the age of 7 years [59]. On the"/>
 <result pre="or exposure to parental smoking are both associated with non-atopic" exact="asthma" post="at age 7 years [59]. A recent study showed"/>
 <result pre="[59]. A recent study showed that the risk of developing" exact="asthma" post="was highest in infants having IgE sensitization and wheeze"/>
 <result pre="observed associations between rhinoviruses, allergic sensitization, and the development of" exact="asthma" post="are not fully understood. It is possible that there"/>
 <result pre="atopic or non-atopic asthma. Treatment of viral wheeze to prevent" exact="asthma" post="Several therapeutic strategies have been shown to alter the"/>
 <result pre="have been shown to alter the natural history of virus-induced" exact="asthma" post="exacerbations (Fig. 5). In general, such treatment would need"/>
 <result pre="and be easy to administer. Fig. 5 Current strategies for" exact="asthma" post="prevention and treatment. Details in text. RV, rhinovirus; RSV,"/>
 <result pre="RSV illness among pre-term infants (72% reduction), those with chronic" exact="lung disease" post="(65% reduction), and hemodynamically significant congenital heart disease (53%"/>
 <result pre="those with chronic lung disease (65% reduction), and hemodynamically significant" exact="congenital heart disease" post="(53% reduction) [68]. The application of palivizumab resulted in"/>
 <result pre="with chronic lung disease (65% reduction), and hemodynamically significant congenital" exact="heart disease" post="(53% reduction) [68]. The application of palivizumab resulted in"/>
 <result pre="recurrent wheezing episodes following hospitalization due to RSV, but not" exact="asthma" post="[11]. Interestingly, a new, second-generation high-affinity derivative of palivizumab"/>
 <result pre="systemic anti-inflammatory management may drastically affect the natural course of" exact="asthma" post="development, probably via targeting pre-existing Th2-skewed immunity and/or virus-induced"/>
 <result pre="following year (by 20–30%) and time to the initiation of" exact="asthma" post="controller medication within the following 5 years (by 30–40%)"/>
 <result pre="days in every case but also with the initiation of" exact="asthma" post="medication within the next 14 months in every case"/>
 <result pre="decrease the subsequent risk for asthma. Long-term sequela Whether RV" exact="bronchiolitis" post="is the cause of severe lung injury, resulting in"/>
 <result pre="lung injury, resulting in subsequent wheezing episodes and development of" exact="asthma" post="or if there is an inborn susceptibility to both"/>
 <result pre="or if there is an inborn susceptibility to both acute" exact="bronchiolitis" post="and subsequent asthma remains still a matter of debate."/>
 <result pre="is an inborn susceptibility to both acute bronchiolitis and subsequent" exact="asthma" post="remains still a matter of debate. Nevertheless, the major"/>
 <result pre="RV, which seem to have a different course in post-bronchiolitis" exact="asthma" post="sequela, apart from underlying lung morbidity (for review, see"/>
 <result pre="number of recurrent wheezing episodes, but the incidence of physician-diagnosed" exact="asthma" post="at age 6 remained intact [74, 75]. These effects,"/>
 <result pre="family history, indicating that RSV infection is not causal to" exact="asthma" post="or atopy development. On the contrary, atopy is associated"/>
 <result pre="atopy development. On the contrary, atopy is associated with childhood" exact="asthma" post="inception after RV-induced bronchiolitis. A study in high-risk birth"/>
 <result pre="experienced RV-induced bronchiolitis, there is a high risk of school-age" exact="asthma" post="(OR 9.8 vs. 2.6; RV vs. RSV), and the"/>
 <result pre="years, who developed RV-induced bronchiolitis, the odds ratio for atopic" exact="asthma" post="at school age was 5.0, which increase up to"/>
 <result pre="up to 12 when combined with early sensitization [59]. RSV-induced" exact="bronchiolitis" post="was neither associated with atopic nor non-atopic asthma [59]."/>
 <result pre="[59]. RSV-induced bronchiolitis was neither associated with atopic nor non-atopic" exact="asthma" post="[59]. Altogether, the above-presented data suggest that airways in"/>
 <result pre="that airways in &quot;high-risk�? individuals display an increased susceptibility for" exact="asthma" post="inception after RV-induced bronchiolitis [77]. Protection of these high-risk"/>
 <result pre="individuals display an increased susceptibility for asthma inception after RV-induced" exact="bronchiolitis" post="[77]. Protection of these high-risk children against the effects"/>
 <result pre="infections during infancy may represent an effective strategy for primary" exact="asthma" post="prevention. Mechanisms of asthma exacerbation Asthma exacerbation is defined"/>
 <result pre="represent an effective strategy for primary asthma prevention. Mechanisms of" exact="asthma" post="exacerbation Asthma exacerbation is defined as an acute or"/>
 <result pre="exacerbation is defined as an acute or subacute worsening of" exact="asthma" post="symptoms and lung function as compared to the patients’"/>
 <result pre="4). However, it is estimated that up to 85–95% of" exact="asthma" post="exacerbations in children and 75–80% in adults are linked"/>
 <result pre="of exacerbation (Fig. 4). The most common viral triggers for" exact="asthma" post="exacerbation are rhinoviruses, particularly subtypes A and C [15]."/>
 <result pre="rhinoviruses, particularly subtypes A and C [15]. Hospital admissions for" exact="asthma" post="exacerbations correlate with a seasonal increase of RV infections"/>
 <result pre="wheeze in infants and young children, can also trigger acute" exact="asthma" post="exacerbation in adults [79]. Human metapneumovirus, influenza, parainfluenza, adenovirus,"/>
 <result pre="parainfluenza, adenovirus, coronavirus, and bocavirus have all been detected in" exact="asthma" post="exacerbations but in lower frequencies [3]. Several mechanisms why"/>
 <result pre="the corresponding gene for CDHR3 has been linked to childhood" exact="asthma" post="with severe asthma exacerbations [32]. Airway epithelial cells form"/>
 <result pre="for CDHR3 has been linked to childhood asthma with severe" exact="asthma" post="exacerbations [32]. Airway epithelial cells form a barrier to"/>
 <result pre="the severity of the viral infection and the risk of" exact="asthma" post="exacerbation are allergic sensitization and the airway microbiome. For"/>
 <result pre="allergic sensitization synergistically increase the risk of exacerbation [3]. Atopic" exact="asthma" post="with allergic sensitization can be associated with reduced virus-induced"/>
 <result pre="neutralizing IgE-mediated inflammation can enhance IFN responses and reduce virus-induced" exact="asthma" post="exacerbations in children [84]. This finding suggests that neutralizing"/>
 <result pre="inflammatory cytokines and mediators causing increased inflammation and risk of" exact="asthma" post="exacerbations (Fig. 4) [85]. In addition, patients with asthma"/>
 <result pre="of asthma exacerbations (Fig. 4) [85]. In addition, patients with" exact="asthma" post="are frequently colonized with bacteria in lower and upper"/>
 <result pre="increase mucus production. However, evidence linking bacterial infections to acute" exact="asthma" post="exacerbation is limited. Treatment of asthma in regard to"/>
 <result pre="bacterial infections to acute asthma exacerbation is limited. Treatment of" exact="asthma" post="in regard to viral infections Exacerbations of asthma are"/>
 <result pre="Treatment of asthma in regard to viral infections Exacerbations of" exact="asthma" post="are characterized by a progressive increase in symptoms of"/>
 <result pre="asthma are characterized by a progressive increase in symptoms of" exact="shortness" post="of breath, cough, wheezing, and progressive decrease in lung"/>
 <result pre="lung function. Viral respiratory infections remain a leading cause of" exact="asthma" post="exacerbations, both in children and adults. The presence of"/>
 <result pre="higher risk of treatment failure [86]. Typically management of all" exact="asthma" post="exacerbations includes a symptomatic treatment increasing doses of beta"/>
 <result pre="by far the most widely used drugs in children with" exact="asthma" post="and have potent anti-inflammatory activity. In recent years, an"/>
 <result pre="and formoterol, and highlights the superiority of combination therapy in" exact="asthma" post="exacerbations over either drug alone. Combination of either salmeterol"/>
 <result pre="infection (for review see Jackson and Johnston [71]). The effective" exact="suppression" post="of growth factors highlighted above certainly represents a plausible"/>
 <result pre="anti-IgE treatment was also shown to markedly reduce infection-induced severe" exact="asthma" post="exacerbations. A year-round treatment with omalizumab has been shown"/>
 <result pre="omalizumab has been shown to abolish the seasonal peaks in" exact="asthma" post="exacerbations, most of which are associated with RV infection"/>
 <result pre="anti-viral responses [88]. Influenza vaccine Influenza contributes to some acute" exact="asthma" post="exacerbations. Children with asthma should remain a priority group"/>
 <result pre="vaccine Influenza contributes to some acute asthma exacerbations. Children with" exact="asthma" post="should remain a priority group for influenza immunization because"/>
 <result pre="exacerbations. Children with asthma should remain a priority group for" exact="influenza" post="immunization because of the newly established association between influenza"/>
 <result pre="for influenza immunization because of the newly established association between" exact="influenza" post="and ED management failure combined with well-recognized influenza-related complications"/>
 <result pre="confirmed by a recent systematic review and meta-analysis, showing that" exact="influenza" post="vaccination reduced the risk of asthma exacerbations [22]. Immunomodulators"/>
 <result pre="and meta-analysis, showing that influenza vaccination reduced the risk of" exact="asthma" post="exacerbations [22]. Immunomodulators and bacterial lysates Among several non-specific"/>
 <result pre="and bacterial lysates Among several non-specific anti-viral approaches to reduce" exact="asthma" post="include strategies aiming at enhancing the patient’s resistance to"/>
 <result pre="of children over half of whom had atopic conditions, including" exact="asthma" post="[90]. Bacterial lysates have recently been proved to reduce"/>
 <result pre="to reduce the number of the recurrent wheezing episodes and" exact="asthma" post="episodes, in patients treated with BL compared with placebo"/>
 <result pre="abundance of data showing that RV-C and RV-A contribute to" exact="asthma" post="development and/or is a marker of asthma susceptibility. Using"/>
 <result pre="RV-A contribute to asthma development and/or is a marker of" exact="asthma" post="susceptibility. Using viral markers in relation to treatment might"/>
 <result pre="have no conflict of interest. References References 1.SelroosOKupczykMKunaPLacwikPBousquetJBrennanDPalkonenSContrerasJFitzGeraldMHedlinGJohnstonSLLouisRMetcalfLWalkerSMoreno-GaldoAPapadopoulosNGRosado-PintoJPowellPHaahtelaTNational and regional" exact="asthma" post="programmes in EuropeEur Respir Rev20152413747448310.1183/16000617.0000811426324809 2.LangDMSevere asthma: epidemiology, burden"/>
 <result pre="3.JarttiTGernJERole of viral infections in the development and exacerbation of" exact="asthma" post="in childrenJ Allergy Clin Immunol2017140489590610.1016/j.jaci.2017.08.00328987219 4.Papadopoulos NG, Christodoulou I,"/>
 <result pre="Xepapadaki P, Zuberbier T (2011) Viruses and bacteria in acute" exact="asthma" post="exacerbations--a GA2LEN-DARE systematic review. Allergy 66(4):458–468. 10.1111/j.1398-9995.2010.02505.x 5.TurunenRKoistinenAVuorinenTArkuBSoderlund-VenermoMRuuskanenOJarttiTThe first"/>
 <result pre="Child Adolesc Health20193641842610.1016/S2352-4642(19)30057-430948251 7.RubnerFJJacksonDJEvansMDGangnonRETislerCJPappasTEGernJELemanskeRFJrEarly life rhinovirus wheezing, allergic sensitization, and" exact="asthma" post="risk at adolescenceJ Allergy Clin Immunol2017139250150710.1016/j.jaci.2016.03.04927312820 8.LehtinenPRuoholaAVantoTVuorinenTRuuskanenOJarttiTPrednisolone reduces recurrent"/>
 <result pre="17.BizzintinoJLeeWMLaingIAVangFPappasTZhangGMartinACKhooSKCoxDWGeelhoedGCMcMinnPCGoldblattJGernJELe SouefPNAssociation between human rhinovirus C and severity of acute" exact="asthma" post="in childrenEur Respir J20113751037104210.1183/09031936.0009241020693244 18.JarttiTGernJERhinovirus-associated wheeze during infancy and"/>
 <result pre="asthma in childrenEur Respir J20113751037104210.1183/09031936.0009241020693244 18.JarttiTGernJERhinovirus-associated wheeze during infancy and" exact="asthma" post="developmentCurr Respir Med Rev20117316016610.2174/15733981179558942323066381 19.BonnelykkeKColemanATEvansMDThorsenJWaageJVissingNHCarlssonCJStokholmJChawesBLJessenLEFischerTKBochkovYAOberCLemanskeRFJrJacksonDJGernJEBisgaardHCadherin-related family member 3 genetics"/>
 <result pre="asthmaAm J Respir Crit Care Med2017196898599210.1164/rccm.201701-0120OC28608756 22.VasileiouESheikhAButlerCEl FerkhKvon WissmannBMcMenaminJRitchieLSchwarzeJPapadopoulosNGJohnstonSLTianLSimpsonCREffectiveness of" exact="influenza" post="vaccines in asthma: a systematic review and meta-analysisClin Infect"/>
 <result pre="meta-analysisClin Infect Dis20176581388139510.1093/cid/cix52428591866 23.ThomsenSFvan der SluisSKyvikKOSkyttheASkadhaugeLRBackerVIncrease in the heritability of" exact="asthma" post="from 1994 to 2003 among adolescent twinsRespir Med201110581147115210.1016/j.rmed.2011.03.00721450446 24.PividoriMSchoettlerNNicolaeDLOberCImHKShared"/>
 <result pre="of childhood asthmaNature2007448715247047310.1038/nature0601417611496 26.SteinMMThompsonEESchoettlerNHellingBAMagnayeKMStanhopeCIgartuaCMorinAWashingtonC3rdNicolaeDBonnelykkeKOberCA decade of research on the 17q12-21" exact="asthma" post="locus: piecing together the puzzleJ Allergy Clin Immunol2018142374976410.1016/j.jaci.2017.12.97429307657 27.CaliskanMBochkovYAKreiner-MollerEBonnelykkeKSteinMMDuGBisgaardHJacksonDJGernJELemanskeRFJrNicolaeDLOberCRhinovirus"/>
 <result pre="activation via regulation of integrins and CD48Nat Commun20134247910.1038/ncomms347924056518 31.ZhangYWillis-OwenSAGSpiegelSLloydCMMoffattMFCooksonWThe ORMDL3" exact="asthma" post="gene regulates ICAM1 and has multiple effects on cellular"/>
 <result pre="study identifies CDHR3 as a susceptibility locus for early childhood" exact="asthma" post="with severe exacerbationsNat Genet2014461515510.1038/ng.283024241537 33.BochkovYAWattersKAshrafSGriggsTFDevriesMKJacksonDJPalmenbergACGernJECadherin-related family member 3, a"/>
 <result pre="with severe exacerbationsNat Genet2014461515510.1038/ng.283024241537 33.BochkovYAWattersKAshrafSGriggsTFDevriesMKJacksonDJPalmenbergACGernJECadherin-related family member 3, a childhood" exact="asthma" post="susceptibility gene product, mediates rhinovirus C binding and replicationProc"/>
 <result pre="Respir Med20186537938810.1016/S2213-2600(18)30052-329496485 37.FornoEWangTQiCYanQXuCJBoutaouiNHanYYWeeksDEJiangYRosserFVonkJMBrouwerSAcosta-PerezEColon-SemideyAAlvarezMCaninoGKoppelmanGHChenWCeledonJCDNA methylation in nasal epithelium, atopy, and atopic" exact="asthma" post="in children: a genome-wide studyLancet Respir Med20197433634610.1016/S2213-2600(18)30466-130584054 38.CardenasASordilloJERifas-ShimanSLChungWLiangLCoullBAHivertMFLaiPSFornoECeledonJCLitonjuaAABrennanKJDeMeoDLBaccarelliAAOkenEGoldDRThe nasal"/>
 <result pre="studyLancet Respir Med20197433634610.1016/S2213-2600(18)30466-130584054 38.CardenasASordilloJERifas-ShimanSLChungWLiangLCoullBAHivertMFLaiPSFornoECeledonJCLitonjuaAABrennanKJDeMeoDLBaccarelliAAOkenEGoldDRThe nasal methylome as a biomarker of" exact="asthma" post="and airway inflammation in childrenNat Commun2019101309510.1038/s41467-019-11058-331300640 39.Bergroth E, Aakula"/>
 <result pre="Camargo CA Jr, Jartti T (2019) Rhinovirus type in severe" exact="bronchiolitis" post="and the development of asthma. J Allergy Clin Immunol"/>
 <result pre="41.BaraldoSContoliMBonatoMSnijdersDBiondiniDBazzanECosioMGBarbatoAPapiASaettaMDeficient immune response to viral infections in children predicts later" exact="asthma" post="persistenceAm J Respir Crit Care Med2018197567367510.1164/rccm.201706-1249LE28862881 42.HaahtelaTA biodiversity hypothesisAllergy20197481445145610.1111/all.1376330835837"/>
 <result pre="hypothesisAllergy20197481445145610.1111/all.1376330835837 43.BisgaardHStokholmJChawesBLVissingNHBjarnadottirESchoosAMWolskHMPedersenTMVindingRKThorsteinsdottirSFolsgaardNVFinkNRThorsenJPedersenAGWaageJRasmussenMAStarkKDOlsenSFBonnelykkeKFish oil-derived fatty acids in pregnancy and wheeze and" exact="asthma" post="in offspringN Engl J Med2016375262530253910.1056/NEJMoa150373428029926 44.RosendahlJValkamaSHolmlund-SuilaEEnlund-CerulloMHauta-AlusHHelveOHytinanttiTLevalahtiEKajantieEViljakainenHMakitieOAnderssonSEffect of higher vs"/>
 <result pre="a history of such illnesses: a randomized clinical trialJAMA2015314192034204410.1001/jama.2015.1389626575060 48.BisgaardHHermansenMNBuchvaldFLolandLHalkjaerLBBonnelykkeKBrasholtMHeltbergAVissingNHThorsenSVStageMPipperCBChildhood" exact="asthma" post="after bacterial colonization of the airway in neonatesN Engl"/>
 <result pre="during rhinovirus infection is associated with increased respiratory symptoms and" exact="asthma" post="exacerbationsJ Allergy Clin Immunol201413351301130710.1016/j.jaci.2014.02.03024698319 51.AmpofoKBenderJShengXKorgenskiKDalyJPaviaATByingtonCLSeasonal invasive pneumococcal disease in"/>
 <result pre="microbiome impacts severity of lower respiratory infection and risk of" exact="asthma" post="developmentCell Host Microbe201517570471510.1016/j.chom.2015.03.00825865368 55.KuruvillaMELeeFELeeGBUnderstanding asthma phenotypes, endotypes, and mechanisms"/>
 <result pre="respiratory infection and risk of asthma developmentCell Host Microbe201517570471510.1016/j.chom.2015.03.00825865368 55.KuruvillaMELeeFELeeGBUnderstanding" exact="asthma" post="phenotypes, endotypes, and mechanisms of diseaseClin Rev Allergy Immunol201956221923310.1007/s12016-018-8712-130206782"/>
 <result pre="inflammationCell2010140677778310.1016/j.cell.2010.03.00420303868 59.LukkarinenMKoistinenATurunenRLehtinenPVuorinenTJarttiTRhinovirus-induced first wheezing episode predicts atopic but not nonatopic" exact="asthma" post="at school ageJ Allergy Clin Immunol2017140498899510.1016/j.jaci.2016.12.99128347734 60.BochkovYAGernJERhinoviruses and their"/>
 <result pre="productionJ Allergy Clin Immunol2014134233234110.1016/j.jaci.2014.01.02924636084 62.JacksonDJMakriniotiHRanaBMShamjiBWTrujillo-TorralboMBFootittJDel-RosarioJTelcianAGNikonovaAZhuJAniscenkoJGogsadzeLBakhsolianiETraubSDhariwalJPorterJHuntDHuntTStanciuLAKhaitovMBartlettNWEdwardsMRKonOMMalliaPPapadopoulosNGAkdisCAWestwickJEdwardsMJCousinsDJWaltonRPJohnstonSLIL-33-dependent type 2 inflammation during rhinovirus-induced" exact="asthma" post="exacerbations in vivoAm J Respir Crit Care Med2014190121373138210.1164/rccm.201406-1039OC25350863 63.BealeJJayaramanAJacksonDJMacintyreJDREdwardsMRWaltonRPZhuJMan"/>
 <result pre="J Respir Crit Care Med2014190121373138210.1164/rccm.201406-1039OC25350863 63.BealeJJayaramanAJacksonDJMacintyreJDREdwardsMRWaltonRPZhuJMan ChingYShamjiBEdwardsMWestwickJCousinsDJYi HwangYMcKenzieAJohnstonSLBartlettNWRhinovirus-induced IL-25 in" exact="asthma" post="exacerbation drives type 2 immunity and allergic pulmonary inflammationSci"/>
 <result pre="Task FThe potential of anti-infectives and immunomodulators as therapies for" exact="asthma" post="and asthma exacerbationsAllergy2018731506310.1111/all.1325728722755 67.Stepanova E, Isakova-Sivak I, Rudenko L"/>
 <result pre="potential of anti-infectives and immunomodulators as therapies for asthma and" exact="asthma" post="exacerbationsAllergy2018731506310.1111/all.1325728722755 67.Stepanova E, Isakova-Sivak I, Rudenko L (2019) Overview"/>
 <result pre="Straus S, Parkin P, Cohen E (2017) International variation in" exact="asthma" post="and bronchiolitis guidelines. Pediatrics 140(5). 10.1542/peds.2017-0092 71.JacksonDJJohnstonSLThe role of"/>
 <result pre="Parkin P, Cohen E (2017) International variation in asthma and" exact="bronchiolitis" post="guidelines. Pediatrics 140(5). 10.1542/peds.2017-0092 71.JacksonDJJohnstonSLThe role of viruses in"/>
 <result pre="Clin Immunol2015135369169810.1016/j.jaci.2014.07.00125129681 73.KoistinenALukkarinenMTurunenRVuorinenTVahlbergTCamargoCAJrGernJRuuskanenOJarttiTPrednisolone for the first rhinovirus-induced wheezing and 4-year" exact="asthma" post="risk: a randomized trialPediatr Allergy Immunol201728655756310.1111/pai.1274928660720 74.MochizukiHKusudaSOkadaKYoshiharaSFuruyaHSimoesEAFcollab: Scientific Committee"/>
 <result pre="Crit Care Med20171961293810.1164/rccm.201609-1812OC28152315 75.ScheltemaNMNibbelkeEEPouwJBlankenMORoversMMNaaktgeborenCAMazurNIWildenbeestJGvan der EntCKBontLJRespiratory syncytial virus prevention and" exact="asthma" post="in healthy preterm infants: a randomised controlled trialLancet Respir"/>
 <result pre="trialLancet Respir Med20186425726410.1016/s2213-2600(18)30055-929500030 76.JacksonDJGangnonREEvansMDRobergKAAndersonELPappasTEPrintzMCLeeWMShultPAReisdorfECarlson-DakesKTSalazarLPDaSilvaDFTislerCJGernJELemanskeRFJrWheezing rhinovirus illnesses in early life predict" exact="asthma" post="development in high-risk childrenAm J Respir Crit Care Med2008178766767210.1164/rccm.200802-309OC18565953"/>
 <result pre="childrenAm J Respir Crit Care Med2008178766767210.1164/rccm.200802-309OC18565953 77.MansbachJMClarkSTeachSJGernJEPiedraPASullivanAFEspinolaJACamargoCAJrChildren hospitalized with rhinovirus" exact="bronchiolitis" post="have asthma-like characteristicsJ Pediatr201617220220410.1016/j.jpeds.2016.01.04126875009 78.JohnstonNWJohnstonSLDuncanJMGreeneJMKebadzeTKeithPKRoyMWasermanSSearsMRThe September epidemic of asthma"/>
 <result pre="rhinovirus bronchiolitis have asthma-like characteristicsJ Pediatr201617220220410.1016/j.jpeds.2016.01.04126875009 78.JohnstonNWJohnstonSLDuncanJMGreeneJMKebadzeTKeithPKRoyMWasermanSSearsMRThe September epidemic of" exact="asthma" post="exacerbations in children: a search for etiologyJ Allergy Clin"/>
 <result pre="Res200531Suppl 17716395866 80.GeorasSNRezaeeFEpithelial barrier function: at the front line of" exact="asthma" post="immunology and allergic airway inflammationJ Allergy Clin Immunol2014134350952010.1016/j.jaci.2014.05.04925085341 81.BasnetSPalmenbergACGernJERhinoviruses"/>
 <result pre="with rhinovirusJ Exp Med2005201693794710.1084/jem.2004190115781584 84.BusseWWMorganWJGergenPJMitchellHEGernJELiuAHGruchallaRSKattanMTeachSJPongracicJAChmielJFSteinbachSFCalatroniATogiasAThompsonKMSzeflerSJSorknessCARandomized trial of omalizumab (anti-IgE) for" exact="asthma" post="in inner-city childrenN Engl J Med2011364111005101510.1056/NEJMoa100970521410369 85.KimCKCallawayZGernJEViral infections and"/>
 <result pre="Immunol Res2018101121710.4168/aair.2018.10.1.1229178673 86.MerckxJDucharmeFMMartineauCZemekRGravelJChalutDPoonaiNQuachCJPRespiratory viruses and treatment failure in children with" exact="asthma" post="exacerbationPediatrics20181421e2017410510.1542/peds.2017-410529866794 87.BatemanEDHurdSSBarnesPJBousquetJDrazenJMFitzgeraldJMGibsonPOhtaKO'ByrnePPedersenSEPizzichiniESullivanSDWenzelSEZarHJGlobal strategy for asthma management and prevention: GINA"/>
 <result pre="treatment failure in children with asthma exacerbationPediatrics20181421e2017410510.1542/peds.2017-410529866794 87.BatemanEDHurdSSBarnesPJBousquetJDrazenJMFitzgeraldJMGibsonPOhtaKO'ByrnePPedersenSEPizzichiniESullivanSDWenzelSEZarHJGlobal strategy for" exact="asthma" post="management and prevention: GINA executive summaryEur Respir J20083114317810.1183/13993003.51387-200718166595 88.TeachSJGergenPJSzeflerSJMitchellHECalatroniAWildfireJBloombergGRKercsmarCMLiuAHMakhijaMMMatsuiEMorganWO'ConnorGBusseWWSeasonal"/>
 <result pre="prevention: GINA executive summaryEur Respir J20083114317810.1183/13993003.51387-200718166595 88.TeachSJGergenPJSzeflerSJMitchellHECalatroniAWildfireJBloombergGRKercsmarCMLiuAHMakhijaMMMatsuiEMorganWO'ConnorGBusseWWSeasonal risk factors for" exact="asthma" post="exacerbations among inner-city childrenJ Allergy Clin Immunol201513561465147310.1016/j.jaci.2014.12.194225794658 89.ColinAARossiGAFeleszkoWImmunomodulation in"/>
 <result pre="Feleszko W (2019) Orally administered immunostimulant as a prevention of" exact="asthma" post="exacerbation and wheezing in children-a systematic review. (Abstract EAACI"/>
</results>
